TLR2 and myelodysplastic syndrome: In fact, a clinical trial using a TLR2 antagonist for the treatment of patients with MDS is currently underway (Opsona Therapeutics, Dublin, Ireland), and thus an understanding of the role of TLR2 signaling in regulating HSCs is highly relevant toward advancing therapy for patients with MDS.